Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
bC2JZ4QzdcPT2mPB